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Abstract
Background: Reductions in breast cancer (BC) mortality in Western countries have been attributed to the use of screening
mammography and adjuvant treatments. The goal of this work was to analyze the contributions of both interventions to
the decrease in BC mortality between 1975 and 2008 in Catalonia.
Methodology/Principal Findings: A stochastic model was used to quantify the contribution of each intervention. Age
standardized BC mortality rates for calendar years 1975–2008 were estimated in four hypothetical scenarios: 1) Only
screening, 2) Only adjuvant treatment, 3) Both interventions, and 4) No intervention. For the 30–69 age group, observed
Catalan BC mortality rates per 100,000 women-year rose from 29.4 in 1975 to 38.3 in 1993, and afterwards continuously
decreased to 23.2 in 2008. If neither of the two interventions had been used, in 2008 the estimated BC mortality would have
been 43.5, which, compared to the observed BC mortality rate, indicates a 46.7% reduction. In 2008 the reduction
attributable to screening was 20.4%, to adjuvant treatments was 15.8% and to both interventions 34.1%.
Conclusions/Significance: Screening and adjuvant treatments similarly contributed to reducing BC mortality in Catalonia.
Mathematical models have been useful to assess the impact of interventions addressed to reduce BC mortality that
occurred over nearly the same periods.
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Introduction
Between 1993 and 2007, breast cancer (BC) mortality rates
decreased 3% annually in Catalonia [1]. Reduction in BC
mortality in Western countries has been attributed to the use of
screening mammography and adjuvant treatments [2], and to
improved quality of care [3,4]. Adjuvant treatment is used after
primary treatments, such as surgery or radiation, to reduce the risk
of relapse. The evaluation of the impact of early detection and
adjuvant treatment on BC mortality reduction is challenging due
to the fact that both interventions spread almost simultaneously.
Mathematical models can overcome this difficulty by estimating
BC mortality under different hypothetical scenarios, based on data
from the literature and BC registries such as the BC natural
history, the stage shift associated with early detection and the
benefit attributed to adjuvant treatments in clinical trials [5].
The goal of this work was to estimate the proportion of BC
mortality reduction attributable to screening and adjuvant
treatments. Previous work from the Cancer Intervention and
Surveillance Modeling Network (CISNET) modeled the BC
mortality trend in the USA [5]. Based on the work of one of
these groups (the Dana-Farber Cancer Institute group) [6], we
used a mathematical model to estimate annual BC mortality in the
Catalan population under four different scenarios: 1) Only screening,
2) Only adjuvant treatments (tamoxifen and multiagent chemotheraphy), 3)
Both interventions, and 4) Background (no intervention).
Methods
Mathematical model
BC mortality by age, birth cohort and calendar year was
estimated using a stochastic model, originally developed by Lee
and Zelen (LZ), that was based on the natural history of the disease
[6]. The main assumptions of the model are: 1) BC is a progressive
disease with four states: disease-free, pre-clinical (where the disease
is present but asymptomatic), clinical (where physical symptoms
are present), and death. 2) Women that participate in screening
may be diagnosed by a screening exam (annual or biennial) or in
the interval between exams, if the disease becomes symptomatic.
Women not participating in screening are diagnosed in the clinical
state. 3) The benefit of screening is due to a favorable shift in the
stage at diagnosis, with a higher proportion of women in early
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stages relative to usual care (see Section 4 in Appendix S1). In the
LZ model, ductal carcinoma in situ (DCIS) cases were not
included. The details and the equations for the LZ model can be
found in previously published works [6,7,8] and in Appendix S1.
We previously obtained inputs and modified some equations in the
model for the Catalan population [9,10,11,12,13].
The LZ model takes into account two important biases that
emerge when assessing the survival time of screen-detected cancer
cases: lead-time and length biases [14]. Lead-time is the length of
time between screening detection of a disease and its clinical
presentation. Even if early detection had no benefit, the survival of
screened individuals would appear longer simply due to the
addition of the lead-time. The LZ model is not affected by lead
time bias because the screen-detected cases have the origin for
which survival is measured at the expected time of clinical
diagnosis. The model assumes that the cases diagnosed earlier
would have been alive at the time the disease would have been
clinically diagnosed. Consequently, there is an implied ‘‘guarantee
time’’ for disease-specific survival. Length bias arises because the
cancers detected in screening examinations are more likely to have
slower growth than symptomatic tumors. The LZ model takes into
account the distribution of sojourn time in the pre-clinical state. As
a result, exam-diagnosed cases are not a random sample of cases in
the pre-clinical state, and tumors with a longer sojourn time in the
pre-clinical state are more likely to be detected by screening.
The output of the model was the number of annual BC
mortality cases for women aged 30–79 and 30–69 years and born
between 1900 and 1975 in the four hypothetical scenarios
mentioned above: 1) Only screening, 2) Only adjuvant treatments, 3)
Both interventions, and 4) Background. BC incidence for women aged
less than 30 years is negligible and death certificates for women 80
years or older may have had low accuracy in past decades. Age
and cohort specific mortality rates were weighted by the age
distribution of the Catalan population at the last year analyzed
(2008) to obtain standardized rates for calendar years between
1975 and 2008. Observed annual rates were smoothed using a
moving average with window size k = 2. The estimations were
obtained using the software Mathematica v7.0.
Inputs of the model
BC incidence. A previously published age-cohort model
that incorporated cohort characteristics like intensity of
mammography utilization and fecundity rate was used [9]. This
model allowed estimations of BC incidence under the assumption
of no screening. Thus, the estimated incidence rates were lower
than the observed rates that included overdiagnosed cases.
Details and parameters for the incidence estimation can be
found in Section 2 in Appendix S1. The estimated incidence was
used to derive the probability of transition from the healthy state
to the pre-clinical state following the method briefly described in
Section 3 in Appendix S1 [15].
Mammography sensitivity, sojourn time, and disease
stage distributions. Values for mammography sensitivity (ranging
from 0.35 to 0.8, varying with age and period, see Section 5 in
Appendix S1), sojourn time in the pre-clinical state (ranging from 2 to 4,
varying with age, see Section 3 in Appendix S1), and stage
distributions were obtained from the literature [6], based on data
from the Breast Cancer Surveillance Consortium (BCSC). The
distribution of stages at diagnosis was less favorable for the non-
screened population than for interval cases or screen-detected
cases, and it was less favorable for biennial screening than for
annual screening (see Section 4 in Appendix S1).
Dissemination of screening mammography. The
dissemination of screening mammography by birth cohort had
been modeled elsewhere using mixed effects models [11]. The
estimates provided the proportion of women that started using
periodic mammography at each specific age and the periodicity of
exams (annual, biennial and irregular) for mammography users
during their lifetimes. Self-declared data was obtained from the
three Catalan Health Surveys in the calendar years 1994, 2002
and 2006 [16,17,18]. Further details can be found in Section 6 in
Appendix S1.
Dissemination of adjuvant treatments. Data on the use of
adjuvant treatments (multiagent chemotherapy and tamoxifen)
during the 1980 s in Catalonia was scarce except for some small
studies [19,20]. Adjuvant treatment was recommended for node
positive patients or for high risk node negative patients [21]. The
GEICAM group reported the use of adjuvant therapy in Spain in
the periods 1990–93 [22] and 1994–97 [23] in two retrospective
observational studies that included more than 15,000 patients
treated in 43 Spanish hospitals, some of them in Catalonia. These
two studies, with some limitations, made it possible to compare the
proportion of women with BC that used adjuvant treatments in
Spain and the USA, in two cross-sections from the 1990 s. This
comparison showed similar levels of treatment use in the two
countries during the 1990 s, with higher levels of use in Spain in
some periods or stage groups (see Table 1). Based on these results,
we assumed that the dissemination of adjuvant treatments during
the 1980 s and the 1990 s was similar in both countries. The
estimate was taken from Mariotto et al. [24,25].
Table 1. Proportion of women with BC who received adjuvant therapies.
USA* Spain**
1990–93 1994–97 1990–93 1994–97
I, II- II+/IIIa I, II- II+/IIIa I, II, III II,III I, II, III II,III
(2) (+) (2) (+)
Chemotherapy 0.22 0.36 0.26 0.39 0.26 0.37 0.18 0.23
Hormonotherapy 0.35 0.31 0.36 0.24 0.39 0.28 0.45 0.17
Both 0.08 0.25 0.10 0.30 0.11 0.33 0.25 0.59
None 0.35 0.08 0.28 0.07 0.23 0.02 0.13 0.01
*Obtained from Mariotto et al. [24]. In this work chemotherapy was restricted to multiagent chemotherapy and hormonotheraphy was restricted to tamoxifen.
**Obtained from the Alamo I study for years 1990–93 and the Alamo II study for 1994–97 [22,23].
Positive and negative signs refer to node affectation. Stratification by BC stage groups differs between the two countries.
doi:10.1371/journal.pone.0030157.t001
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Survival functions. The BC age- and stage-probability
density functions (pdfs) for BC survival were assumed to be
independent of the mode of diagnosis. The survival distribution of
each mode of diagnosis (usual care, screen-detection, interval case)
was a mixture of age- and stage-pdfs weighted by the corresponding
stage distribution (Section 4 in Appendix S1).
The Catalan survival functions by age and stage for the period
1980–89 were obtained in a previous study [13]. These functions
correspond to the pre-screening era in Spain, so they are not
affected by lead-time bias.
To introduce the benefit of adjuvant treatments, first the age-
and stage-specific Catalan survival functions were adjusted to the
mortality reduction reported by clinical trials (Section 4.1 in
Appendix S1). Then, the chronological survival pdfs were a
mixture of the treatment adjusted pdfs weighted by the proportion
of women receiving each adjuvant treatment option, as indicated
by the dissemination of adjuvant treatments.
BC mortality trends under different scenarios
Age-specific BC mortality rates and the standardized mortality
rate were estimated for each calendar year in the four hypothetical
scenarios, as indicated in the following sections.
1) Background: with no screening and no adjuvant
treatments, M0. The Catalan 1980–89 survival functions and
the stage distributions at BC diagnosis that corresponded to no
screening (Section 4 in Appendix S1) were used for women
diagnosed at any calendar year of the studied period.
2) Only screening, MSc. First, BC mortality was estimated
assuming that 100% of women from each cohort were in one of
the following situations: a) no-screening, b) annual screening
(starting at ages 40, 50 or 60) or biennial screening (starting at ages
40, 50 or 60). Second, BC deaths for each birth cohort and
calendar year were estimated by taking into account the
dissemination of mammography over time. Thus, BC deaths,
obtained as indicated in the first step, were weighted by the
proportion of women using periodic mammography at the mid-
interval of the screening starting at ages 45, 55 and 67.5 years,
respectively. According to the observed data, and for all age
groups, it was assumed that 65% of the screened women had
annual mammograms and 35% had biennial ones [11]. Changes
in these proportions changed the final results slightly (data not
shown). This process was done using the 1980–89 Catalan survival
functions. In this scenario, stage distributions corresponding to
screen-detected cases and interval cases, specific for annual and
biennial exams, were used (Section 4 in Appendix S1).
3) Only adjuvant treatments, MAdj. The 1980–89 Catalan
survival hazard functions (pre-screening) were multiplied by the
hazard ratios corresponding to the benefit of adjuvant treatments
(tamoxifen, multiagent chemotherapy or both) and were weighted
by adjuvant treatment dissemination in the US, over time. In this
way, the effect of the adjuvant treatments modified the pre-
screening survival functions towards a more favorable prognosis.
In this scenario stage distributions that corresponded to a non-
screened population were used (Section 4 in Appendix S1).
4) Both interventions screening and adjuvant treatments,
MBoth. BC deaths under this scenario were estimated by
combining the steps described in the only screening and the only
adjuvant treatment scenarios. It is important to notice that when
combining screening and adjuvant treatments in the mathematical
model there is a synergy between the two interventions, defined as
MSczMAdj{MBoth. This synergy is negative, meaning that the
benefit of screening is larger without adjuvant treatments than it
would be with them, and vice versa.
Mortality reduction
The next step was to assess the benefit of each intervention. For
each scenario x, the relative mortality reduction was estimated by
comparing the standardized BC mortality rates of the correspond-
ing scenario Mxð Þ with the Background M0ð Þ. Relative estimates of
benefit are less sensitive to misspecification in models and enable
to compare different populations [2].
Mortality reductions were estimated at the end of the period
(calendar year 2008) using the formula,
MRxZ 2008ð Þ~100i 1{Mx 2008ð Þ
M0 2008ð Þ
 
,
and for the period where BC mortality decreased, since 1990 to
2008, using the formula
MRx 1990{2008ð Þ~100: 1{
P2008
i~1990 Mx ið ÞP2008
i~1990 M0 ið Þ
 !
:
Results
Figure 1A shows BC mortality rates for the age group 30–79
years: observed rates (dots), predictions for the Background (gray
line) and for the Only screening scenario (green line). The model
overestimates the observed BC mortality rates. This is not an
unexpected result, since the model was not calibrated to reproduce
the observed mortality. Adjusting the predicted rates to the
observed mortality rate in 1975 would allow to use our model to
estimate the impact of screening and adjuvant treatments in the
30–79 age group.
Figure 1B replicates Figure 1A for the age interval 30–69 years.
Figure 1B shows an acceptable agreement between observed and
predicted mortality rates during the late 1970 s and the 1980 s,
when screening and adjuvant treatments were scarcely used in
Catalonia. For this reason, we assessed the impact of screening and
adjuvant treatments in the 30–69 age interval.
Figure 1B shows that observed BC mortality rates per 100,000
women, 30–69 years old, rose from 29.4 in 1975 to 38.3 in 1993.
Afterwards, rates continuously decreased to 23.2 in 2008. The
Background shows a continuously increasing trend reaching a value
of 43.5 in 2008. Compared to the observed rate in 2008 (23.2), the
overall percentage reduction in BC mortality at the end of the
studied period was estimated as 46.7%.
Figure 2 adds to Figure 1B the expected trend if Only adjuvant
treatments had been used (cyan line) and the expected trend if Both
interventions, screening and adjuvant treatments, had been used
(magenta line). Before the 1990 s, mortality under the different
scenarios was very similar to the Background. The scenarios Only
screening and Only adjuvant treatments show that screening and
adjuvant treatments had similar effects on mortality. The scenario
that combines Both interventions screening and adjuvant treatments
did not fit the observed BC mortality rates. During the late 1980 s
and early 1990 s the model-predicted BC mortality underestimat-
ed the observed rates. There was agreement during the late
1990 s, but during the 2000 s, the model-predicted BC mortality
rates overestimated the observed ones.
Table 2 shows that, at the end of the studied period (year 2008),
Only screening leads to a 20.4% mortality reduction, Only adjuvant
treatments to a 15.8% reduction, and Both interventions to a 34.1%
reduction. This indicates that approximately 3/4 (34.1%/
46.7% = 0.73) of the mortality reduction at the end of the studied
Modeling Breast Cancer Mortality Reduction
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30157
period can be attributed similarly to screening and adjuvant
treatments, and 1/4 remains unexplained. Attributable mortality
reductions for the period 1990–2008 were 12.7% for Only screening,
12.4% for Only adjuvant treatments, and 23.7% for Both interventions.
Reductions for the 1990–2008 period are lower than the
reductions at the end (2008) because they represent an average
of the period.
Sensitivity analysis
A sensitivity analysis was performed to measure the robustness of
the results and also to help in understanding the lack of agreement
between the observed and estimated rates in the 30–69 age interval
during the 1990 s and the 2000 s. Changes in the shape and the
level of BC mortality were explored by modifying two of the inputs
of the model: survival functions and dissemination of adjuvant
treatments.
Adding an improvement in the survival functions. The
motivation was that other causes than screening and adjuvant
treatment seem to play an important role in BC mortality
reduction. Survival for Catalan women diagnosed in 1980–89 was
worse than for US women diagnosed in 1975–79 (pre-screening
era in the US), and the survival functions in Catalonia and the US
were similar during the 1990–2001 period. The reasons why the
differences in survival between the two countries disappeared are
unknown and may be attributed to a plethora of improvements
that we refer to as Other causes. These may include changes in BC
care like the introduction of multidisciplinary teams or changes in
population attitudes like higher health awareness. For this reason,
the baseline survival functions were changed. An improvement in
survival for women diagnosed since 1995 was analyzed by
substituting the 1980–89 Catalan survival functions (considered
pre-screening in Catalonia) with the 1975–79 US survival
functions (considered pre-screening in the USA). Figure 3A
shows the BC mortality estimations with and without this
improvement in the survival functions. The change in the
functions caused that estimations were closer to the observed
rates from 1995 to 2008.
To get closer to the observed mortality rates, a second change
was added to the improvement in the survival functions.
Adding a delay in adjuvant treatment dissemination. The
motivation was that the model underestimated the rates around the
1990 s and that using the same dissemination as in the USA could
overestimate the use of adjuvant treatments in Catalonia. Figure 3B
shows the impact of changing the year when adjuvant treatments
began to be used from 1975 to 1990, and to 1995, and assuming
that the level of use after the start point was the same as in the US.
The results show similar estimated values after the year 2000, and
different delays quickly converge to the same levels of BC mortality.
The later the introduction of adjuvant treatments, the closer the
estimated and the observed rates, improving the shape of the model.
Mortality reductions. To assess the robustness of the results
we also estimated the BC mortality reductions for the model that
best fitted the observed data and which assumes a) the
introduction of adjuvant treatments began in 1995 and b) after
1995 the survival pdfs were the US ones. Figure 4 shows the
estimated BC mortality rates under the different scenarios for this
model. The Only screening scenario is the same in Figure 4 as before
the sensitivity analysis (Figure 2) because the sensitivity analysis did
Figure 1. BC mortality rates and screening. Standardized BC mortality rates for the age groups: A) 30–79, B) 30–69. Observed rates (dots) and
estimations under different scenarios Background (gray) and Only screening (green).
doi:10.1371/journal.pone.0030157.g001
Figure 2. BC mortality rates and different scenarios. Standard-
ized BC mortality rates for the age group 30–69. Observed rates (dots)
and estimations under different scenarios Background (gray), Only
screening (green), Only adjuvant treatments (cyan), and Both interven-
tions (magenta).
doi:10.1371/journal.pone.0030157.g002
Modeling Breast Cancer Mortality Reduction
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30157
not change any assumptions about screening. The Only adjuvant
treatment estimates are higher in Figure 4 because delays in the
implementation of treatments cause higher mortalities, but levels
in 2008 are similar in Figures 4 and 2.The Other causes scenario
(blue line in Figure 4) shows that this is the individual scenario with
the highest decrease of BC mortality with respect the Background.
The Screening + Adjuvant treatments + Other causes scenario estimates
(magenta line in Figure 4) show agreement with observed rates.
Table 3 shows that the contribution of screening and adjuvant
treatments to BC mortality reduction remains stable at the end of
the studied period (year 2008). Only screening lead to a 20.4%
mortality reduction, Only adjuvant treatments to a 15.7% reduction,
Other causes to 25.7%, and Screening + Adjuvant treatments + Other causes
scenario to a 52.1% reduction. The synergy in the sensitivity
analysis was 29.7%.This value is high if compared with the
mortality reductions. Synergy increases as more interventions are
considered in the model and indicates that once a strategy has a
high impact in decreasing the mortality, the potential of other
interventions decreases.
In summary, the mortality estimations obtained with the initial
model and after changes in the sensitivity analysis were different,
but mortality reductions attributable to screening and adjuvant
treatments at the end of the studied period, year 2008, were
similar.
Discussion
Main findings
Our results suggest that mammography screening and adjuvant
treatments have contributed significantly to the reduction in BC
mortality in recent decades in Catalonia. For the year 2008, the
observed BC mortality rate in the 30–69 age group was around
half of the expected rate if none of the two interventions had been
introduced (Background). The contribution of screening with
mammography and adjuvant treatments were similar and together
accounted for 3/4 of the overall BC mortality reduction at the end
of the studied period. The remaining reduction not explained by
the model could be ascribed to other factors, e.g. better BC
awareness, advances in surgical procedures or improved health
care infrastructure and organization.
The goal of the study was to assess the contributions of
screening and adjuvant therapy on BC mortality trends, and this
was more closely related to the shape of the trend than to the
mortality level. Our initial aim was to assess the impact of
screening and adjuvant therapy in women 30–79 years old, but we
restricted our analysis to the 30–69 age interval because the
predicted mortality rates of our model in the pre-interventions era
fitted the data better.
There was also a lack of fit between the observed and expected
BC mortality trends in two time periods. Our model underesti-
mated mortality during the late 1980 s and early 1990 s and
overestimated mortality during the 2000 s. Possible reasons for not
capturing the trend could be 1) the presence of moderate or large
errors in some of the inputs or model assumptions, or small errors
in most of the inputs. For instance, the fact that the model provides
a good approximation for observed data in the pre-screening
period for the 30–69 age interval, but not the 30–79 age interval,
could be due to the assumption of ‘‘guarantee time’’ between early
detection and clinical diagnosis. This assumption may bias the
estimated BC mortality rates as women get older, when competing
causes of death have a higher impact.
The unexplained portion of the mortality decline can be used to
generate hypotheses as to what else was affecting mortality during
the studied period. The sensitivity analysis showed that observed
Figure 3. Sensitivity analysis. Standardized BC mortality rates for the age group 30–69. Observed rates (dots) and estimations for All interventions
scenario. A) Changing the BC survival pdfs by the US pdfs for women diagnosed since 1995. B) Changing the year of introduction of adjuvant
treatments: 1975, 1990, and 1995 (from bottom to top).
doi:10.1371/journal.pone.0030157.g003
Table 2. Percent decline compared to Background for the year 2008 and the period 1975–2008.
BC mortality reduction compared to Background:
Only screening Only adjuvant treatments Both interventions Synergy
2008 20.4 15.8 34.1 22.1
1990–2008 12.7 12.4 23.7 21.4
doi:10.1371/journal.pone.0030157.t002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30157
BC mortality rates could be better estimated when we changed the
model assumptions related to dissemination of adjuvant treatments
and survival functions. Several facts can explain this result. First,
the model used the US data on adjuvant treatment dissemination.
Delays in the dissemination of adjuvant treatment in Catalonia
could have affected the measurement of the impact of adjuvant
treatments on the observed mortality reduction. Second, the fact
that survival in Catalonia during the 1980 s was worse than in the
US in 1975–1979, but the differences disappeared during the
1990 s [13], is compatible with improvements in factors other than
mammography screening or adjuvant treatments. For example, a
stage shift in diagnosis due to greater health awareness or better
BC management strategies may have contributed significantly to
the observed mortality decline. In Norway the implementation of
multidisciplinary teams specializing in BC care was identified as an
important element in the reduction of BC mortality [3]. Third,
during the 2000 s, there have been improvements in surgery,
radiotherapy, and chemotherapy, as well as hormone treatments
and biological therapies like trastuzumab [26]. These advances
were not taken into account in the initial analysis, and could
partially explain the better fit when the survival functions were
modified in the sensitivity analysis.
In the majority of Western countries, BC is the malignant tumor
with the highest incidence among women (almost 1/3 of all
malignant neoplasms). In Catalonia, the decrease in BC mortality
rates during the 1990 s was similar to that in other countries in
Europe, although the change-points and the mortality levels
differed [27]. Since dissemination of screening with mammogra-
phy and adjuvant treatments overlapped during the 1990 s and
the early 2000 s, the separate contribution of each intervention is
difficult to assess unless using mathematical models. Our findings
are important because they assess the benefit of early detection in
the context of continuously increasing survival by using more
effective treatments. For instance, the synergism between screen-
ing and adjuvant treatment was 21.7. When other causes are also
considered in the sensitivity analysis, the synergism increases to
29.7. This shows that the potential impact of reducing BC
mortality with screening decreases as long as the contribution of
treatments or other causes increases.
Comparison with other studies. The model used to
estimate BC mortality was developed by the Dana-Farber
Cancer Institute researchers Lee and Zelen [6]. These scientists
together with six other groups modeled the US BC mortality
trend, under the CISNET initiative. The CISNET groups’
evaluation of the impact of screening and adjuvant treatments
on US BC mortality reduction provided estimates of the
percentage decline in the year 2000, ranging from 7.5% to
22.7% for screening with mammography, from 12% to 20.8% for
adjuvant treatments, for the 30–79 age interval. Our results for the
year 2000 are within the CISNET range, for the 30–79 age group
(data not shown). Compared to the USA, one of the differences
was the high percent of mortality decline attributable to other
causes in Catalonia. In our sensitivity analysis, other causes had a
similar contribution than screening and adjuvant treatments.
Given that the pre-screening survival functions for Catalonia were
worse than in the USA, there was more space for a potential
improvement in Catalonia.
Our results differ from the results obtained by Vervoort et al. in
the Netherlands [28]. They used the computer simulation model
MIcrosimulation SCreening ANalysis (MISCAN) to assess the
effect of adjuvant therapy and mammography screening on BC
mortality. They predicted that the reduction in BC mortality due
to adjuvant therapy was 7% in women aged 55–74 years, while the
reduction due to screening at 10 years after the screening program
was fully implemented would be 28–30%. Of the estimated total
BC mortality reduction of 34%, approximately 80% would be
explained by screening, whereas 20% could be attributed to
adjuvant therapy.
Kalager et al. also quantified the effect of screening on BC
mortality in Norway [3]. The authors compared BC mortality
between periods 1985–1995 and 1996–2005. Among screened
women, there was a 28% relative reduction in mortality between
the two groups, but screening accounted for only about 1/3 of the
total reduction. Although the methods used by the authors and our
Figure 4. BC mortality rates and different scenarios. Standard-
ized BC mortality rates for the age group 30–69. Observed rates (dots)
and estimations under different scenarios Background (gray), Only
screening (green), Only adjuvant treatments (cyan), Other causes (dark
blue), and All interventions (magenta).
doi:10.1371/journal.pone.0030157.g004
Table 3. Percent decline compared to Background for the year 2008 and the period 1975–2008.
Sensitivity analysis, BC mortality reduction compared to Background:
Only screening Only adjuvant treatments Other causes All interventions Synergy
2008 20.4 15.7 25.7 52.1 29.7
1990–2008 12.7 8.2 15.3 29.4 26.8
‘‘All interventions’’ includes Screening + Adjuvant treatments + Other causes.
doi:10.1371/journal.pone.0030157.t003
Modeling Breast Cancer Mortality Reduction
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approximation are completely different, the estimation of the
impact of screening on BC mortality reduction is similar and lower
than predicted in older clinical trials. The fact that BC treatment
has improved considerably in recent years reduces the potential
benefits of screening. In an extreme scenario where treatments
cured all BC cases, the screening benefit would be negligible.
Limitations. This study also has limitations. The main one
was the limited information on the dissemination of adjuvant
treatments. The two observational studies performed in Spain by
the GEICAM group during the 1990 s indicated that the use of
adjuvant treatments was similar to or higher than that reported in
the USA [29] for the same periods. It could be that doctors
participating in the GEICAM studies tended to use adjuvant
therapy earlier and/or more frequently than doctors in other
Catalan hospitals [22,23], especially in the late 1980 s and the
beginning of the 1990 s when it was not clear if node negative
patients would benefit [21]. For this reason, in the sensitivity
analysis, it was assumed that a) the use of adjuvant treatments was
the same as in the USA after 1990 but was negligible before 1990
and b) the same as in a) but with the time point of 1995. The
observed BC mortality rates, higher than those predicted by the
model in both situations a) and b), indicated that BC survival in
the late 1980 s and early 1990 s was lower in Catalonia than in the
US. This result is consistent with a previous analysis by our group
[13].
Second, the model relies on data and assumptions that may not
be correct. When available, Catalan data from population-based
registries or BC screening programs has been used. If the input
data was not available at the regional or country level, data from
the literature, or that the CISNET had prepared for BC mortality
modeling research groups in the US [5], was used. For instance,
the stage distribution for screen-detected cases that we have used
may be affected by a certain level of overdiagnosis of tumours with
limited malignant potential [30,31]. High levels of overdiagnosis
would result in a overestimation of the impact of screening on BC
mortality reduction.
Third, confidence intervals for the model outputs were not
obtained. Our model is probabilistic because it works with the pdfs
of the different inputs related to the natural history or detection of
BC. It is also an analytic model that consists of a set of equations
describing BC mortality over time. There is uncertainty associated
with the model inputs and there is also uncertainty associated with
the model structure. It is complex and computationally intensive to
obtain the variance of the model estimates. Instead, a sensitivity
analysis to explore how changes in the input parameters affect the
results was carried out. For example, when the dissemination of
the adjuvant treatments was delayed, all the estimations converged
to the same levels at the end of studied period. This provides
confidence on the robustness of the model.
Strengths. To our knowledge, in Europe the number of
studies that address the simultaneous quantification of the
contribution of mammography screening and adjuvant
treatments in BC mortality reduction is scarce. The results
obtained are consistent with the estimations of other groups for the
USA and Norway, which indicates robustness of the model to
departures of the assumptions or to data differences.
It seems that in Catalonia causes other than screening and
adjuvant treatments also contributed to BC mortality reduction.
The identification of these other causes is challenging and may
provide further information for a deeper evaluation of all the
interventions that had an impact on the BC mortality reduction.
This work also suggests that some health information registries
need to be improved, both at the clinical and population level in
Catalonia.
Conclusion
In conclusion, our study supports the hypothesis that mam-
mography screening, adjuvant treatments and other factors have
played an important role in the decline of BC mortality.
Approximately 3/4 of mortality reduction can be attributed with
similar weight to screening and adjuvant treatments. Probability
models have been useful to assess the impact of interventions to
reduce BC mortality which occurred over nearly the same periods.
Supporting Information
Appendix S1 contains details of the mathematical model as well
as additional tables and input values.
(PDF)
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